部門紹介

研究業績

最終更新日 : 2025年5月9日

目次

  1. 原著論文
  2. 解説・総説や教科書など

原著論文

2025年｜2024年｜2023年｜2022年｜2021年｜2020年｜2019年｜2018年｜2017年｜2016年｜2015年｜2014年｜2013年｜2012年｜2011年｜2010年｜2009年

2025年

Miyashita Y, *Tajima K, Izumi K, Matsumoto N, Hayakawa D, Nakamura IT, Katayama I, Wibowo A, Matsuda H, Winardi W, Amien BR, Mitsuishi Y, Takahashi F, Nakamura K, Uchibori K, Yanagitani N, Hayashi T, Takamochi K, Suzuki K, Katayama R, Takahashi K.
Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra-Terminal Domain Inhibitors. Cancer Sci. 2025 May;116(5):1392-1404. doi: 10.1111/cas.70032.
Utsumi T, Mizuta H, Seto Y, Uchibori K, Nishio M, Okamoto I, *Katayama R.
AXL-Mediated Drug Resistance in ALK-Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts. Cancer Sci. 2025 Apr;116(4):1034-1047. doi: 10.1111/cas.70006.
Maruyama K, Shimizu Y, Nomura Y, Oh-hara T, Takahashi Y, Nagayama S, Fujita N, *Katayama R.
Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization. NPJ Precis Oncol.: 2025 Jan 6;9(1):4. doi: 10.1038/s41698-024-00793-6.
Takagi S, Nakajima M, Koike S, Takami M, Sugiura Y, Sakata S, Baba S, Takemoto A, Saito M, Funauchi Y, Ae K, Takeuchi K, Fujita N, *Katayama R.
Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma. Oncogene. 2025 Apr;44(12):794-804. doi: 10.1038/s41388-024-03251-6.
Furugaki, K., Fujimura, T., Sakaguchi, N., Watanabe, Y., Uchibori, K., Miyauchi, E., Hayashi, H., *Katayama, R., *Yoshiura, S.
Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK-inhibitor-induced tolerant persister cells in ALK-fusion-positive lung cancer. Molecular Oncology: 2025 Feb;19(2):519-539. doi: 10.1002/1878-0261.13746.

2024年

Mori K, Suzuki T, Waki U, Hayashi S, Kadono S, Kawahara R, Takeuchi M, Mizuta H, Dohmae N, Katayama R, *Simizu S.
Identification of C-mannosylation in a receptor tyrosine kinase AXL.　Glycobiology. 2024 Sep 30;34(11):cwae096. doi: 10.1093/glycob/cwae096.
Oyama Y, Shimada K, Miyata H, Iida-Norita R, Emori C, Kamoshita M, Oura S, Katayama R, Matzuk MM, Ikawa M.
Inhibition of ROS1 activity with lorlatinib reversibly suppresses fertility in male mice. Andrology. 2024 Nov 20. doi: 10.1111/andr.13808.
Fujimura T, Furugaki K, Mizuta H, Muraoka S, Nishio M, Adachi J, Uchibori K, Miyauchi E, Hayashi H, *Katayama R, *Yoshiura S.
Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer. NPJ Precis Oncol. 2024 Nov 17;8(1):264.
Wei, X., Uchibori, K., Kondo, N., Utsumi, T., Takemoto, A., Koike, S., Takagi, S., Yanagitani, N., Nishio, M., *Katayama, R.
MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer. Cancer Lett.: 2024 Nov 1;604:217220. doi: 10.1016/j.canlet.2024.217220.
Takahashi, Y., Morimura, R., Tsukamoto, K., Gomi, S., Kato, A., Mizukami, M., Naito, Y., Irie, S., Nagayama, S., Shinozaki, E., Yamaguchi, K., Fujita, N., Kitano, S., Katayama, R., Matsusaki, M.
In vitro throughput screening of anticancer drugs using patient-derived cell lines cultured on vascularized three-dimensional stromal tissues. Acta biomaterialia, 183: 111-129, 2024, doi: 10.1016/j.actbio.2024.05.037.
Sasaki, N., Asano, Y., Sorayama, Y., Kamimura, C., Kitano, S., Irie, S., Katayama, R., Shimoda, H., Matsusaki, M.
Promoting Biological Similarity by Collagen Microfibers in 3D Colorectal Cancer-Stromal Tissue: Replicating Mechanical Properties and Cancer Stem Cell Markers. Acta biomaterialia, 2024 Sep 1;185:161-172. doi: 10.1016/j.actbio.2024.07.001.
Chen, M., Mashima, T., Oishi, T., Muramatsu, Y., Seto, Y., Takamatsu, M., Kawata, N., Morino, S., Nakamura, A., Inaba, S., Yuan, X., Maruyama, K., Suzuki, M., Sato, A., Yoshida, H., Jang, M. K., Mizutani, A., Takeuch, K., Yamaguchi, K., Shirai, F., Nagayama, S., Katayama, R., *Seimiya, H.
APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells. British Journal of Cancer, 130 (1): 151-162, 2024
Morino, S., Mashima, T., Shirai, F., Nagayama, S., Katayama, R., Seimiya, H.
BET protein?dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer. Cancer Lett., 584: 216632, 2024
Nagasaka, M., Miyajima, C., Inoue, Y., Hashiguchi, S., Suzuki, Y., Morishita, D., Aoki, H., Toriuchi, K., Katayama, R., Aoyama, M., Hayashi, H.
ID3 is a novel target gene of p53 and modulates lung cancer cell metastasis. Biochem. Biophys. Res. Commun., 708: in press, 2024
Otomo, K., Omura, T., Nozawa, Y., Edwards, S. J., Sato, Y., Saito, Y., Yagishita, S., Uchida, H., Watakabe, Y., Naitou, K., Yanai, R., Sahara, N., Takagi, S., Katayama, R., Iwata, Y., Shiokawa, T., Hayakawa, Y., Otsuka, K., Watanabe-Takano, H., Haneda, Y., Fukuhara, S., Fujiwara, M., Nii, T., Meno, C., Takeshita, N., Yashiro, K., Rosales Rocabado, J. M., Kaku, M., Yamada, T., Oishi, Y., Koike, H., Cheng, Y., Sekine, K., Koga, J. I., Sugiyama, K., Kimura, K., Karube, F., Kim, H., Manabe, I., Nemoto, T., Tainaka, K., Hamada, A., Brismar, H., Susaki, E. A.
descSPIM: an affordable and easy-to-build light-sheet microscope optimized for tissue clearing techniques. Nature Communications, 15 (1): 4941, 2024
Shiraishi, A., Oh-Hara, T., Takahashi, Y., Uchibori, K., Nishio, M., Katayama, R.
3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer. Biochem. Biophys. Res. Commun., 725 (17): 150255, 2024
Suzuki, M., Uchibori, K., Oh-Hara, T., Nomura, Y., Suzuki, R., Takemoto, A., Araki, M., Matsumoto, S., Sagae, Y., Kukimoto-Niino, M., Kawase, Y., Shirouzu, M., Okuno, Y., Nishio, M., Fujita, N., *Katayama, R.
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer.　NPJ Precis. Oncol., 8 (1): 46, 2024

2023年

Fujiwara, H., Nagayama, S., Kawachi, H., Nakano, K., Shimizu, Y., Katayama, R., Yao, R., Komai, Y., Hiyoshi, Y., Mukai, T., Yamaguchi, T., Nagasaki, T., Akiyoshi, T., Fukunaga, Y.
A case of laparoscopically resected rectal neuroendocrine carcinoma and its renal metastasis with a potential sensitivity to inhibitors of FGFR and the Bcl family. J. Surg., 8 (7): 1759, 2023
Katayama, Y., Yamada, T., Tanimura, K., Tokuda, S., Morimoto, K., Hirai, S., Matsui, Y., Nakamura, R., Ishida, M., Kawachi, H., Yoneda, K., Hosoya, K., Tsuji, T., Ozasa, H., Yoshimura, A., Iwasaku, M., Kim, Y. H., Horinaka, M., Sakai, T., Utsumi, T., Shiotsu, S., Takeda, T., Katayama, R., Takayama, K.
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer. NPJ Precis. Oncol., 7 (1): 12, 2023
Kondo, N., Utsumi, T., Shimizu, Y., Takemoto, A., Oh-Hara, T., Uchibori, K., Subat-Motoshi, S., Ninomiya, H., Takeuchi, K., Nishio, M., Miyazaki, Y., Katayama, R.
MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF. JCI insight, 8 (24): e173688, 2023
Suezawa, T., Sasaki, N., Yukawa, Y., Assan, N., Uetake, Y., Onuma, K., Kamada, R., Tomioka, D., Sakurai, H., Katayama, R., Inoue, M., Matsusaki, M.
Ultra-rapid and specific gelation of collagen molecules for transparent and tough gels by transition metal complexation. Adv. Sci. (Weinh): e2302637, 2023
Yoshida, T., Kumagai, T., Toyozawa, R., Katayama, R., Nishio, M., Seto, T., Goto, K., Yamamoto, N., Ohe, Y., Kudou, K., Asato, T., Zhang, P., Nakagawa, K.
Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial. Cancer Sci., 114 (9): 3698-3707, 2023

2022年

Takemoto A, Takagi S, Ukaji T, Gyobu N, Kakino M, Takami M, Kobayashi A, Lebel M, Kawaguchi T, Sugawara M, Tsuji-Takayama K, Ichihara K, Funauchi Y, Ae K, Matsumoto S, Sugiura Y, Takeuchi K, Noda T, Katayama R, and Fujita N,
Targeting podoplanin for the treatment of osteosarcoma. Clin Can Res. 28 (12): 2633-2645, 2022
Ito K, Nagata K, *Ohta S, Matsuda Y, Ukai T, Yasuda I, Ota A, Kobayashi R, Mio Kabata M, Sankoda N, Maeda T, Woltjen K, Yang L, Maruyama R, Katayama R,Yamamoto T, *Yamada Y,
The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets. Cell Reports.in press
Shimizu Y, Okada K, Adachi J, Abe Y, Narumi R, Uchibori K, Yanagitani N, Koike S, Takagi S, Nishio M, Fujita N, *Katayama R.
GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer. npj Precis Onc. 6: 16 (2022)
Tanimura K, *Yamada T, Okada K, Nakai K, Horinaka M, Katayama Y, Morimoto K, Ogura Y, Takeda T, Shiotsu S, Ichikawa K, Watanabe S, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Taniguchi H, Yoneda K, Matoba S, Sakai T, Uehara H, Yano S, Kusaba T, Katayama R, and Takayama K,
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features. npj Precis Onc. 6: 5 (2022)
Sagawa R, Sakata S, Gong B, Seto Y, Takemoto A,, Takagi S, Ninomiya H, Yanagitani N, Nakao M, Mun M, Uchibori K, Nishio M, Miyazaki Y, Shiraishi Y, Ogawa S, Kataoka K, Fujita N, Takeuchi K, *Katayama R.
Soluble PD-L1 through alternative polyadenylation works as a decoy in lung cancer immunotherapy. JCI insight. 7(1):e153323, 2022.

2021年

Takagi S, Sasaki Y, Koike S, Takemoto A, Seto Y, Haraguchi M, Ukaji T, Kawaguchi T, Sugawara M, Saito M, Funauchi Y, Ae K, Matsumoto S, Fujita N, *Katayama R.
Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis. Oncogene. 2021 Jul 23, 40:5548-5558, doi: 10.1038/s41388-021-01956-6.
Oguri, T., Sasada, S., Seki, S., Murata, S., Tsuchiya, Y., Ishioka, K., Takahashi, S., Seki, R., Hirose, S., Katayama, R., Nakamura, M.
A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation. Respir. Med. Case Rep. 33: 101405 (2021).
Tachiwana H, Dacher M, Maehara K, Harada A, Seto Y, Katayama R, Ohkawa Y, Kimura H, Kurumizaka H, Saitoh N.
Chromatin structure-dependent histone incorporation revealed by a genome-wide deposition assay. Elife. 2021 May 10;10:e66290.
Yoshizawa T, Uchibori K, Araki M, Matsumoto S, Ma B, Kanada R, Seto Y, Oh-hara T, Koike S, Ariyasu R, Kitazono S, Ninomiya H, Takeuchi K, Yanagitani N, Takagi S, Kishi, K, Fujita N, Okuno Y, Nishio M, *Katayama R.
Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity. npj Precis Onc. April 16, 5, 32 (2021).
Ariyasu R, Uchibori K, Sasaki T, Tsukahara M, Kiyotani K, Yoshida R, Ono Y, Kitazono S, Ninomiya H, Ishikawa Y, Mizukami Y, Yanagitani N, Fujita N, Nishio M, *Katayama R.
Monitoring EGFR C797S mutation in Japanese NSCLC patients with serial cell free DNA evaluation using digital droplet PCR. Cancer Sci. 2021 Jun;112(6):2371-2380.
Ukaji T, Takemoto A, Shibata H, Kakino M, Takagi S, Katayama R, Fujita N.
Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents. Cancer Sci. 2021 Jun;112(6):2299-2313.
Mizuta H, Okada K, Araki M, Adachi J, Takemoto A, Kutkowska J, Maruyama K, Yanagitani N, Oh-Hara T, Watanabe K, Tamai K, Friboulet L, Katayama K, Ma B, Sasakura Y, Sagae Y, Kukimoto-Niino M, Shirouzu M, Takagi S, Simizu S, Nishio M, Okuno Y, Fujita N, *Katayama R.
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. Nature Commun. 2021 Feb 24;12(1):1261.
Furuta H, Araki M, Masago K, Sagae Y, Fujita S, Seto K, Shimizu J, Horio Y, Sasaki E, Hosoda W, Katayama R, Okuno Y, Hida T.
Novel resistance mechanisms including L1196Q, P1094H, and R1248_D1249insertion in three patients with non-small-cell lung cancer following ALK tyrosine kinase inhibitor treatment. J Thorac Oncol. 2021 Mar;16(3):477-482.

2020年

Ariyasu R, Yanagitani N, Tadokoro K, Yamaguchi T, Uchibori K, Kitazono S, Fujita N, *Katayama R, *Nishio M.
Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms. Cancer Chemother Pharmacol. 2020 Oct;86(4):517-525.
Papadopoulos KP, Borazanci E, Shaw AT, Katayama R, Shimizu Y, Zhu VW, Sun TY, Wakelee HA, Madison R, Schrock AB, Senaldi G, Nakao N, Hanzawa H, Masaya T, Isoyama T, Nakamaru K, Deng C, Li M, Fran F, Zhao Q, Gao Y, Seto T, Janne PA, Ou SI.
US phase 1 first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2020 Sep 15;26(18):4785-4794.
Ono F, Chiba S, Isaka Y, Matsumoto S, Ma B, Katayama R, Araki M, Okuno Y.
Improvement in predicting drug sensitivity changes associated with protein mutations using a molecular dynamics based alchemical mutation method. Sci Rep. 2020 Feb 7;10(1):2161.
Arai S, Takeuchi S, Fukuda K, Taniguchi H, Nishiyama A, Tanimoto A, Satouchi M, Yamashita K, Ohtsubo K, Nanjo S, Kumagai T, Katayama R, Nishio M, Zheng MM, Wu YL, Nishihara H, Yamamoto T, Nakada M, Yano S.
Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer. J Thorac Oncol. 2020 Jan 21. pii: S1556-0864(20)30022-8.
Yanagitani N, Uchibori K, Koike S, Tsukahara M, Kitazono S, Yoshizawa T, Horiike A, Ohyanagi F, Tambo Y, Nishikawa S, Fujita N, *Katayama R, Nishio M.
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms. Cancer Sci. 2020 Mar;111(3):932-939.
Takahashi K, Seto Y, Okada K, Uematsu S, Uchibori K, Tsukahara M, Oh-Hara T, Fujita N, Yanagitani N, Nishio M, Okubo K, *Katayama R.
Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer. Thorac Cancer. 2020 Mar;11(3):581-587.

2019年

Katayama R, Gong B, Togashi N, Miyamoto M, Kiga M, Iwasaki S, Kamai Y, Tominaga Y, Takeda Y, Kagoshima Y, Shimizu Y, Seto Y, Oh-hara T, Koike S, Nakao N, Hanzawa H, Watanabe K, Yoda S, Yanagitani N, Hata A, Shaw AT, Nishio M, Fujita N, Isoyama T.
The new-generation selective ROS1/NTRK Inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nature Commun.. 2019; Aug 9;10(1):3604.
Gong B., Kiyotani K., Sakata S., Nagano S., Kumehara S., Baba S., Besse B., Yanagitani N., Friboulet L., Nishio M., Takeuchi K., Kawamoto H., Fujita N., *Katayama, R.
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med, 216(4):982-1000. (2019)
Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Yanagitani N, Nishio M, Yano S.
Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status. Cancer Res. in press, (2019)
Okada, K., Araki, M., Sakashita, T., Ma, B., Kanada, R., Yanagitani, N., Horiike, A., Koike, S., Oh-Hara, T., Watanabe, K., Tamai, K., Maemondo, M., Nishio, M., Ishikawa, T., Okuno, Y., Fujita, N. and *Katayama, R.
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. EBioMedicine, 41:105-119. (2019)

2018年

Ukaji T, Takemoto A, Katayama R, Takeuchi K, and *Fujita N.
A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (Macaca fascicularis). Oncotarget, 9, 33322-33336 (2018)
Sakamoto K, Katayama R, Asaka R, Sakata S, Baba S, Nakasone H, Koike S,Tsuyama N, Dobashi A, Sasaki M, Ichinohasama R, Takakuwa E, Yamazaki R, Takizawa J, Maeda T, Narita M, Izutsu K, Kanda Y, Ohshima K, Takeuchi K.
Recurrent 8q24rearrangement in blastic plasmacytoid dendritic cell neoplasm: association withimmunoblastoid cytomorphology, MYC expression, and drug response. Leukemia. 2018 May 23.
Gong, B., Oh-Hara, T., Fujita, N. and *Katayama, R.
3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer. Biochem. Biophys. Res. Commun.,501:527-533. (2018)
Uchibori, K., Inase, N., Nishio, M., Fujita, N. and *Katayama, R.
Identification of mutation accumulation as resistance mechanism emerging in first-line osimertinib treatment. J. Thorac. Oncol., 13:915-925. (2018)
Krishnan H, Rayes J, Miyashita T, Ishii G, Retzbach EP, Sheehan SA, Takemoto　A, Chang YW, Yoneda K, Asai J, Jensen L, Chalise L, Natsume A, Goldberg GS
Podoplanin - an emerging cancer biomarker and therapeutic target. Cancer Science in press (2018)
Katayama R.
Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer. Cancer Science. 109:572-580. (2018)
Ariyasu R, Nishikawa S, Uchibori K, Oh-Hara T, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Kitazono S, Yanagitani N, Horiike A, Inase N, Kasahara K, *Nishio M, *Katayama R
High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer. Lung Cancer, 117: 1-6 (2018)

2017年

Ohashi Y, Okamura M, Katayama R, Fang S, Tsutsui S, Akatsuka A, Shan M, Choi HW, Fujita N, Yoshimatsu K, Shiina I, Yamori T, Dan S.
Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors. Oncotarget, 9:1641-1655. (2017)
Fuse, M.J., Okada, K., Oh-hara, T., Ogura, H., Fujita, N. and Katayama, R.
Mechanisms of resistance to NTRK inhibitors and therapeutic strategies in NTRK1-rearranged cancers. Mol. Cancer Ther., 16:2130-2143. (2017)
Takemoto, A., Miyata, K. and Fujita, N.
Platelet-activating factor podoplanin: from discovery to drug development.
Cancer and metastasis reviews, 36, 225-234 (2017)
Ogura, H., Nagatake-Kobayashi, Y., Adachi, J., Tomonaga, T., Fujita, N. and Katayama, R.
TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.
Sci. Rep., 7, 5519 (2017)
R. Katayama.
Therapeutic strategies and mechanisms of drug resistance in Anaplastic Lymphoma Kinase (ALK)-rearranged lung cancer. Pharmacol. Ther., 117, 1-8 (2017)
Miyata, K., Takemoto, A., Okumura, S., Nishio, M. and Fujita, N.
Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation.
Sci. Rep., 7, 4059 (2017)
Uchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., Fujita, N., Katayama, R.
Brigatinib overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nature Commun, 8: 14768 (2017).
Takemoto, A., Okitaka, M., Takagi, S., Takami, M., Sato, S., Nishio, M., Okumura, S., Fujita, N.
A critical role of platelet TGF-β release in podoplanin-mediated tumour invasion and metastasis. Sci Reports, 7: 42186 (2017).
Takeuchi, S., Fukuda, K., Yamada, T., Arai, S., Takagi, S., Ishii, G., Ochiai, A., Iwakiri, S., Itoi, K., Uehara,H., Nishihara, H., Fujita, N., Yano, S.
Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and contact inhibition. Cancer Sci, In press (2017).
Tanaka, N., Mashima, T., Mizutani, A., Sato, A., Aoyama, A., Gong, B., Yoshida, H., Muramatsu,Y., Nakata, K., Matsuura, M., Katayama, R., Nagayama, S., Fujita, N., Sugimoto, Y., Seimiya H.
APC mutations as a predictive biomarker for sensitivity to tankyrase inhibitors in colorectal cancer.Mol Cancer Ther. 2017 Apr;16(4):752-762.

このページのTOPへ

2016年

Katayama, R., Sakashita, T., Yanagitani, N., Ninomiya, H., Horiike, A., Friboulet, L., Gainor, J. F., Motoi, N., Dobashi, A., Sakata, S., Tambo, Y., Kitazono, S., Sato, S., Koike, S., Iafrate, A. J., Mino-Kenudson, M., Ishikawa, Y., Shaw, A. T., Engleman, J. A., Takeuchi, K., Nishio, M., Fujita, N.
P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. EBioMedicine, 3, 54-66 (2016)
Shaw, A. T., Friboulet, L., Leshchiner, I., Gainor, J. F., Berggvist, S., Brooun, A., Burke, B. J., Deng, Y. L., Liu, W., Dardaei, L., Frias, R. L., Schultz, K. R., Logan, J., James, L. P., Smeal, T., Timofeevski, S., Katayama, R., Iafrate, A. J., Le, L., McTigue, M., Getz, G., Johnson, T. W., Engelman, J. A.
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. N Engl J Med, 374: 54-61 (2016)
Sekiguchi, T., Takemoto, A., Takagi, S., Takatori, K., Sato, S., Takami, M., Fujita, N.
Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Oncotarget, 7, 3934-3946 (2016)
J. F. Gainor, L. Dardaei, S. Yoda, L. Friboulet, I. Leshchiner, R. Katayama, I. Dagogo-Jack, S. Gadgeel, K. Schultz, M. Singh, E. Chin, M. Parks, D. Lee, R. H. DiCecca, E. Lockerman, T. Huynh, J. Logan, L. L. Ritterhouse, L. P. Le, A. Muniappan, S. Digumarthy, C. Channick, C. Keyes, G. Getz, D. Dias-Santagata, R. S. Heist, J. Lennerz, L. V. Sequist, C. H. Benes, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman and A. T. Shaw.
Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer.
Cancer Discov., 6, 1118-1133 (2016)

このページのTOPへ

2015年

Katayama, R., Kobayashi, Y., Friboulet, L., Lockerman, E.L., Koike, S., Shaw, A.T., Engelman, J.A., Fujita, N.
Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive cancer.
Clin Cancer Res, 21, 166-174 (2015)
Hu, D., Gur, M., Zhou, Z., Gamper, A., Hung, M. C., Fujita, N., Lan, L., Bahar, I., Wan, Y.
Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis.
Nat Commun, 6, 8419 (2015)
Niederst, M. J., Sequist, L. V., Poirier, J. T., Mermel, C. H., Lockerman, E. L., Garcia, A. R., Katayama, R., Costa, C., Ross, K. N., Moran, T., Howe, E., Fulton, L. E., Mulvey, H. E., Bernardo, L. A., Mohamoud, F., Miyoshi, N., VanderLaan, P. A., Costa, D. B., Janne, P. A., Borger, D. R., Ramaswamy, S., Shioda, T., Iafrate, A. J., Getz, G., Rudin, C. M., Mino-Kenudson, M., Engelman, J. A.
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun, 6, 6377 (2015)
Yamada, T., Amann, J. M., Fukuda, K., Takeuchi, S., Fujita, N., Uehara, H., Iwakiri, S., Itoi, K., Shilo, K., Yano, S., Carbone, D. P.
Akt kinase-interacting protein Aki1 signals through CREB to drive diffuse malignant mesothelioma. Cancer Res, 75, 4188-4197 (2015)
Zou, H. Y., Friboulet, L., Kodack, D. P., Engstrom, L. D., Li, Q., West, M., Tang, R. W., Wang, H., Tsaparikos, K., Wang, J., Timofeevski, S., Katayama, R., Dinh, D. M., Lam, H., Lam, J. L., Yamazaki, S., Hu, W., Patel, B., Bezwada, D., Frias, R. L., Lifshits, E., Mahmood, S., Gainor, J. F., Affolter, T., Lappin, P. B., Gukasyan, H., Lee, N., Deng, S., Jain, R. K., Johnson, T. W., Shaw, A. T., Fantin, V. R., Smeal, T.
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell, 28, 70-81 (2015)

このページのTOPへ

2014年

Aoyama, A., Katayama, R., Oh-hara, T., Sato, S., Okuno, Y., Fujita, N.
Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
Mol Cancer Ther, 13, 2978-2990 (2014)
Chowdhury, M.M., Danoy, M., Rahman, F., Shinohara, M., Kaneda, S., Shiba, K., Fujita, N., Fujii, T., Sakai, Y.
Adhesion of pancreatic cancer cells in a liver-microvasculature mimicking coculture correlates with their propensity to form liver-specific metastasis in vivo.
Biomed Res Int, 2014, 241571 (2014)
Friboulet, L., Li, N., Katayama, R., Lee, C.C., Gainor, J.F., Crystal, A.S., Michellys, P.Y., Awad, M.M., Yanagitani, N., Kim, S., Pferdekamper, A.C., Li, J., Kasibhatla, S., Sun, F., Sun, X., Hua, S., McNamara, P., Mahmood, S., Lockerman, E.L., Fujita, N., Nishio, M., Harris, J.L., Shaw, A.T., Engelman, J.A.
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Cancer Discov, 4, 662-673 (2014)
Katayama, R., Friboulet, L., Koike, S., Lockerman, E.L., Khan, T.M., Gainor, J.F., Iafrate, A.J., Takeuchi, K., Taiji, M., Okuno, Y., Fujita, N., Engelman, J.A., Shaw, A.T.
Two novel ALK mutations mediate acquired resistance to the next-generation AKL inhibitor alectinib.
Clin Cancer Res, 20, 5686-5696 (2014)
Miyata, K., Takagi, S., Sato, S., Morioka, H., Shiba, K., Minamisawa, T., Takami, M., Fujita, N.
Suppression of Aggrus/podoplanin-induced platelet aggregation and pulmonary metastasis by a single-chain antibody variable region fragment.
Cancer Med, 3, 1595-1604 (2014)
Ohtsubo, K., Yamada, T., Zhao, L., Jin, T.F., Takeuchi, S., Mouri, H., Yamashita, K., Yasumoto, K., Fujita, N., Kitagawa, H., Ohta, T., Ikeda, H., Yano, S.
Expression of Akt kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer.
Pancreas, 43, 1093-1100 (2014)
Pond, A.L., Nedele, C., Wang, W.H., Wang, X., Walther, C., Jaeger, C., Bradley, K.S., Du, H., Fujita, N., Hockerman, G.H., Hannon, K.M.
The mERG1a channel modulates skeletal muscle MuRF1, but not MAFbx, expression.
Muscle Nerve, 49, 378-388 (2014)
Takagi, S., Oh-Hara, T., Sato, S., Gong, B., Takami, M., Fujita, N.
Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis.
Int J Cancer, 134, 2605-2614 (2014)
Takagi, S., Takemoto, A., Takami, M., Oh-Hara, T., Fujita, N.
Platelets promote osteosarcoma cell growth through activation of the platelet-derived growth factor receptor-Akt signaling axis.
Cancer Sci, 105, 983-988 (2014)

このページのTOPへ

2013年

Katayama, R., Aoyama, A., Yamori, T., Qi, J., Oh-Hara, T., Song, Y., Engelman, J.A., Fujita, N.
Cytotoxic activity of Tivanitib (ARQ 197) is not due solely to c-MET inhibition.
Cancer Res, 73, 3087-3096 (2013)
Takagi, S., Sato, S., Oh-Hara, T., Takagi, M., Koike, S., Mishima, Y., Hatake, K., Fujita, N.
Platelets promote tumor growth and metastasis via direct interaction between Aggrus/Podoplanin and CLEC-2.
PLoS One, 8, e73609 (2013)
Yamada, T., Takeuchi, S., Fujita, N., Nakamura, A., Wang, W., Li, Q., Oda, M., Mitsudomi, T., Yatabe, Y., Sekido, Y., Yoshida, J., Higashiyama, M., Noguchi, M., Uehara, H., Nishioka, Y., Sone, S., Yano, S.
Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations.
Oncogene, 32, 4427-4435 (2013)

このページのTOPへ

2012年

Fujita, N., Takagi, S.
The impact of Aggrus/podoplanin on platelet aggregation and tumor metastasis.
J Biochem, 152, 407-413 (2012)
Hahne, J.C., Honig, A., Meyer, S.R., Gambaryan, S., Walter, U., Wischhusen, J., Haussler, S.F., Segerer, S.E., Fujita, N., Dietl, J., Engel, J.B.
Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro.
Oncol Rep, 28, 2023-2028 (2012)
Mohanty, A.R., Kan, Q., Srivastava, S., Uranbileg, B., Arakawa-Takeuchi, S., Fujita, N., Okayama, H.
Successive phosphorylation of p27Kip1 protein at serine-10 and C-terminus crucially controls its cotency to inactivate cdk2.
J Biol Chem, 287, 21757-21764 (2012)

このページのTOPへ

2011年

Ehata, S., Johansson, E., Katayama, R., Koike, S., Watanabe, A., Hoshino, Y., Katsuno, Y., Komuro, A., Koinuma, D., Kano, M.R., Yashiro, M., Hirakawa, K., Aburatani, H., Fujita, N., Miyazono, K.
Transforming growth factor-β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells.
Oncogene, 30, 1693-1705 (2011)
Konishi, S., Yasuchika, K., Ishii, T., Fukumitsu, K., Kamo, N., Fujita, N., Ikai, I., Uemoto, S.
A transmembrane glycoprotein, gp38, is a novel marker for immature hepatic progenitor cells in fetal mouse livers.
In Vitro Cell Dev Biol Anim, 47, 45-53 (2011)
Morishita, D., Takami, M., Yoshikawa, S., Katayama, R., Sato, S., Kukimoto-Niino, M., Umehara, T., Shirouzu, M., Sekimizu, K., Yokoyama, S., Fujita, N.
Cell-permeable carboxyl-terminal p27Kip1 peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.
J Biol Chem, 286, 2681-2688 (2011)
Nakazawa, Y., Arai, H., Fujita, N.
The novel metastasis promoter Merm1/Wbscr22 enhances tumor cell survival in the vasculature by suppressing Zac1/p53-dependent apoptosis.
Cancer Res, 71, 1146-1155 (2011)
Nakazawa, Y., Takagi, S., Sato, S., Oh-Hara, T., Koike, S., Takami, M., Arai, H., Fujita, N.
Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies.
Cancer Sci, 102, 2051-2057 (2011)

このページのTOPへ

2010年

Katayama, R., Ishioka, T., Takada, S., Takada, R., Fujita, N., Tsuruo, T., Naito, M.
Modulation of Wnt signaling by the nuclear localization of cellular FLIP-L.
J Cell Sci, 123, 23-28 (2010)
Misawa, A., Katayama, R., Koike, S., Tomida, A., Watanabe, T., Fujita, N.
AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells.
Oncol Res, 19, 23-33 (2010)
Nakamura, A., Naito, M., Arai, H., Fujita, N.
Mitotic phosphorylation of Aki1 at Ser208 by cyclin B1-Cdk1 complex.
Biochem Biophys Res Commun, 393, 872-876 (2010)
Péterfy, M., Harris, T.E., Fujita, N., Reue, K.
Insulin-stimulated interaction with 14-3-3 promotes cytoplasmic localization of lipin-1 in adipocytes.
J Biol Chem, 285, 3857-3864 (2010)

このページのTOPへ

2009年

Demers, M.J., Thibodeau, S., Noel, D., Fujita, N., Tsuruo, T., Gauthier, R., Arguin, M., Vachon, P.H.
Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1.
J Cell Biochem, 107, 639-654 (2009)
Katayama, R., Koike, S., Sato, S., Sugimoto, Y., Tsuruo, T., Fujita, N.
Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.
Cancer Sci, 100, 2060-2068 (2009)
Nakamura, A., Arai, H., Fujita, N.
Centrosomal Aki1 and cohesin function in separase-regulated centriole disengagement.
J Cell Biol, 187, 607-614 (2009)
Tanaka, H., Hoshikawa, Y., Oh-hara, T., Koike, S., Naito, M., Noda, T., Arai, H., Tsuruo, T., Fujita, N.
PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-κB activation.
Mol Cancer Res, 7, 557-569 (2009)

このページのTOPへ